News Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-12-05 pm EST			5-day change	1st Jan Change
225.85 ^USD	+0.41%		-1.81%	+14.93%

Dec. 02	Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Albuterol Sulfate Inhalation Aerosol	CI
Dec. 02	Iqvia announces strategic collaboration with AWS, naming AWS as preferred agentic cloud provider to power next-generation AI platform	RE

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Albuterol Sulfate Inhalation Aerosol	Dec. 02	CI
Iqvia announces strategic collaboration with AWS, naming AWS as preferred agentic cloud provider to power next-generation AI platform	Dec. 02	RE
IQVIA Names AWS as Preferred Agentic Cloud Partner for New AI Platform	Dec. 02	MT
IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform	Dec. 02	BU
Morgan Stanley Raises Price Target on IQVIA Holdings to $265 From $250, Keeps Overweight Rating	Dec. 02	MT
Jefferies Adjusts Price Target on IQVIA Holdings to $270 From $255, Maintains Buy Rating	Dec. 02	MT
Amneal Announces U.S. Fda Approval of Cyclosporine Ophthalmic Emulsion 0.05%	Dec. 01	CI
HSBC Adjusts Price Target on IQVIA Holdings Inc to $270 From $250, Maintains Buy Rating	Dec. 01	MT
Lupin Gets US FDA Nod for Biosimilar Armlupeg	Nov. 30	MT
Shandong Boan Biotechnology Co., Ltd. Receives Marketing Approval for its Aflibercept Intravitreous Injection, Boyoujing	Nov. 26	CI
Zydus Lifesciences Limited Receives Final Approval from Usfda for Leuprolide Acetate Injection, 14 Mg/2.8Ml (1 Mg/0.2 Ml) Multiple-Dose Vial	Nov. 14	CI
BMO Capital Initiates IQVIA Holdings at Outperform With $260 Price Target	Nov. 13	MT
Atea Pharmaceuticals, Inc. Announces Research Findings, Including Evidence of A Unique Dual Mechanism of Action for Bemnifosbuvir Against Hepatitis C Virus and the Expansion of the Company's Antiviral Pipeline with A New Hepatitis E Virus Program	Nov. 12	CI
IQVIA Holdings Inc. Presents at UBS Global Healthcare Conference 2025, Nov-11-2025 12:30 PM	Nov. 11
Dr. William G. Kaelin Jr. joins IQVIA board of directors	Nov. 05	RE
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors	Nov. 05	BU
IQVIA Appoints William G. Kaelin Jr. to its board of directors, Effective November 5, 2025	Nov. 05	CI
TD Cowen Downgrades IQVIA Holdings to Hold From Buy, Adjusts Price Target to $215 From $206	Nov. 03	MT
Thousands of patients from Scotland's poorest areas to benefit from landmark UK government-funded obesity study	Nov. 03	AQ
Iqvia Holdings Insider Sold Shares Worth $12,461,119, According to a Recent SEC Filing	Oct. 31	MT
Iqvia Holdings Insider Sold Shares Worth $878,800, According to a Recent SEC Filing	Oct. 31	MT
Mizuho Securities Adjusts IQVIA Price Target to $250 From $225	Oct. 31	MT
Rothschild & Co Redburn Adjusts IQVIA Holdings Price Target to $254 From $214	Oct. 30	MT
Jefferies Adjusts Price Target on IQVIA Holdings Inc to $255 From $225, Maintains Buy Rating	Oct. 29	MT
JPMorgan Lifts Price Target on IQVIA to $255 From $177, Maintains Overweight Rating	Oct. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Filters